Intarcia Therapeutics

OverviewSuggest Edit

Intarcia Therapeutics is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System – medicines that have the potential to transform the prevention and management of serious chronic diseases. The Сompany's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. 

... Show more
TypePrivate
Founded1997
HQBoston, USMap
Websiteintarcia.com
Employee Ratings3.2More
View Jobs (14)

Locations

Intarcia Therapeutics is headquartered in
Boston, United States

Location Map
All Locations (3)

Latest Updates

Employees (est.) (Feb 2019)318
Job Openings14

Key People/Management at Intarcia Therapeutics

Kurt Graves

Kurt Graves

Chairman, President and CEO, Intarcia Therapeutics, Inc
James Ahlers

James Ahlers

Vice President, Finance and Operations Chief Financial Officer
Thomas Alessi

Thomas Alessi

Vice President, Development and Manufacturing
FACE Michelle Baron

FACE Michelle Baron

Vice President, Clinical Research Chief Medical Officer
Paul Feldman

Paul Feldman

Head of Discovery and Translational Medicine
Anthony Hurley

Anthony Hurley

Vice President, Global Technical Operations
Show more

Intarcia Therapeutics Office Locations

Intarcia Therapeutics has offices in Boston, Durham and Hayward
Boston, US (HQ)
1 Marina Park Drive
Durham, US
6 Davis Drive
Hayward, US
24650 Industrial Boulevard
Show all (3)
Report incorrect company information

Intarcia Therapeutics Financials and Metrics

Summary Metrics

Founding Date

1997

Intarcia Therapeutics total Funding

$1.9 b

Intarcia Therapeutics latest funding size

$215 m

Time since last funding

2 years ago

Intarcia Therapeutics investors

Omega Funds, Kayon Partners, New Enterprise Associates, Alta Partners, New Leaf Venture Partners, The Pritzker Organization, RA Capital Management, The Baupost Group, Venrock, GGV Capital, Quadrille Capital, Marker, Farallon Capital Management, Fidelity Investments, Baillie Gifford, Foresite Capital
Intarcia Therapeutics's latest funding round in September 2016 was reported to be $215 m. In total, Intarcia Therapeutics has raised $1.9 b. Intarcia Therapeutics's latest valuation is reported to be $3.9 b.
View all funding rounds

Intarcia Therapeutics Revenue

Market valuation

3.9b
Show all financial metrics
Report incorrect company information

Competitors

Sarepta Therapeutics
Healthcare - Public
Zogenix
Healthcare - Public
Merial
Healthcare - Subsidiary
Marinus Pharmaceuticals
Healthcare - Public
Compare competitors

Intarcia Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Intarcia Therapeutics Company Life and Culture

Report incorrect company information

 Intarcia Therapeutics Frequently Asked Questions

  • When was Intarcia Therapeutics founded?

    Intarcia Therapeutics was founded in 1997.

  • Who are Intarcia Therapeutics key executives?

    Intarcia Therapeutics's key executives are Kurt Graves, James Ahlers and Thomas Alessi.

  • How many employees does Intarcia Therapeutics have?

    Intarcia Therapeutics has 318 employees.

  • Who are Intarcia Therapeutics competitors?

    Competitors of Intarcia Therapeutics include Sarepta Therapeutics, Zogenix and Merial.

  • Where is Intarcia Therapeutics headquarters?

    Intarcia Therapeutics headquarters is located at 1 Marina Park Drive, Boston.

  • Where are Intarcia Therapeutics offices?

    Intarcia Therapeutics has offices in Boston, Durham and Hayward.

  • How many offices does Intarcia Therapeutics have?

    Intarcia Therapeutics has 3 offices.